M. A. Bukys, Brandon Bakos, Solomon Afelik, Baruch Zimmerman, B. Barbaro, D. Lin, P. Vaca, T. Goldman, A. Rotem, M. Damaser, J. Oberholzer, U. Barkai, J. Jensen
{"title":"Xeno-Transplantation of macro-encapsulated islets and Pluripotent Stem Cell-Derived Pancreatic Progenitors without Immunosuppression.","authors":"M. A. Bukys, Brandon Bakos, Solomon Afelik, Baruch Zimmerman, B. Barbaro, D. Lin, P. Vaca, T. Goldman, A. Rotem, M. Damaser, J. Oberholzer, U. Barkai, J. Jensen","doi":"10.19104/JORM.2017.109","DOIUrl":"https://doi.org/10.19104/JORM.2017.109","url":null,"abstract":"Islet transplantation effectively treats diabetes but relies on immune suppression and is practically limited by the number of cadaveric islets available. An alternative cellular source is insulin-producing cells derived from pluripotent cell sources. Three animal cohorts were used in the current study to evaluate whether an oxygen-providing macro-encapsulation device, 'βAIR', could function in conjunction with human embryonic stem cells (hESCs) and their derivatives. The first cohort received macro-encapsulated undifferentiated hESCs, a second cohort received hESCs differentiated to a pancreatic progenitor state with limited endocrine differentiation. A reference cohort received human islets. Macro-encapsulation devices were implanted subcutaneously and monitored for up to 4 months. Undifferentiated pluripotent stem cells did not form teratoma but underwent cell death following implantation. Human C-peptide (hC- peptide) was detectable in host serum one week after implantation for both other cohorts. hC-peptide levels decreasing over time but remained detectable up to the end of the study. Key factors associated with mature endocrine cells were observed in grafts recovered from cohorts containing islets and hESC-derivatives including C-peptide, insulin, glucagon and urocortin 3. We conclude that the 'βAIR' macroencapsulation device is compatible with both human islets and pluripotent derivatives, but has a limited capability of sustaining undifferentiated pluripotent cells.","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"122 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88256348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Al-Anazi, J. Bacal, Nihad Mokhtar, Mohammed Kawari, H. Alhashmi, O. Abduljalil, E. Alshaibani, P. Kalogiannidis, A. Estanislao, A. AlJatham, AlBahrani At, K. Akkari
{"title":"A Young Patient with Refractory Multiple Myeloma and Dialysis-Dependent Renal Failure has been Cured by Non-Cryopreserved Autologous Stem Cell Transplantation Followed by Live-Related Kidney Transplantation","authors":"K. Al-Anazi, J. Bacal, Nihad Mokhtar, Mohammed Kawari, H. Alhashmi, O. Abduljalil, E. Alshaibani, P. Kalogiannidis, A. Estanislao, A. AlJatham, AlBahrani At, K. Akkari","doi":"10.21767/2575-7725.100013","DOIUrl":"https://doi.org/10.21767/2575-7725.100013","url":null,"abstract":"Management of patients with multiple myeloma having dialysis-dependent renal failure, particularly if the disease is refractory to several lines of therapy, is a difficult task. Cure of such patients represents a real challenge to the treating team. In late November 2009, the diagnosis of multiple myeloma was made in a young patient who had been receiving regular hemodialysis for end-stage renal disease. His myeloma was refractory to four lines of therapy and it responded partially to the fifth line of treatment. Thereafter, the patient received a noncryopreserved autologous hematopoietic stem cell transplantation which brought his myeloma under more optimal control. One year later, he received live-related kidney transplantation. During his subsequent follow-up for fifty four months post-renal transplantation at King Fahad Specialist Hospital in Dammam, Saudi Arabia, no complication has been encountered. As the case is complicated, the literature review will be detailed in order to discuss the various aspects related to care of the patient presented.","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88311802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haidong Huang, Kevin Yu, Alireza Mohammadi, Efstathios Karanthanasis, Andrew Godley, Jennifer S Yu
{"title":"It's Getting Hot in Here: Targeting Cancer Stem-like Cells with Hyperthermia.","authors":"Haidong Huang, Kevin Yu, Alireza Mohammadi, Efstathios Karanthanasis, Andrew Godley, Jennifer S Yu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cancer stem-like cells (CSCs) are a subset of cancer cells that are resistant to conventional radiotherapy and chemotherapy. As such, CSCs have been recognized as playing a large role in tumor initiation and recurrence. Although hyperthermia is broadly used in cancer treatment either alone or in combination with radio- or chemo-therapy, its potential to target CSCs is not well understood. In this review, we discuss different types of hyperthermia and potential mechanisms of action in cancer treatment, particularly in regards to killing CSCs.</p>","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"2 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/68/nihms938338.PMC6287629.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36764801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yan Yin, Congxing Lin, Ivy Zhang, Alexander V Fisher, Maulik Dhandha, Liang Ma
{"title":"Homeodomain Transcription Factor Msx-2 Regulates Uterine Progenitor Cell Response to Diethylstilbestrol.","authors":"Yan Yin, Congxing Lin, Ivy Zhang, Alexander V Fisher, Maulik Dhandha, Liang Ma","doi":"10.19104/jstb.2015.105","DOIUrl":"https://doi.org/10.19104/jstb.2015.105","url":null,"abstract":"<p><p>The fate of mouse uterine epithelial progenitor cells is determined between postnatal days 5 to 7. Around this critical time window, exposure to an endocrine disruptor, diethylstilbestrol (DES), can profoundly alter uterine cytodifferentiation. We have shown previously that a homeo domain transcription factor MSX-2 plays an important role in DES-responsiveness in the female reproductive tract (FRT). Mutant FRTs exhibited a much more severe phenotype when treated with DES, accompanied by gene expression changes that are dependent on <i>Msx2</i>. To better understand the role that MSX-2 plays in uterine response to DES, we performed global gene expression profiling experiment in mice lacking <i>Msx2</i> By comparing this result to our previously published microarray data performed on wild-type mice, we extracted common and differentially regulated genes in the two genotypes. In so doing, we identified potential downstream targets of MSX-2, as well as genes whose regulation by DES is modulated through MSX-2. Discovery of these genes will lead to a better understanding of how DES, and possibly other endocrine disruptors, affects reproductive organ development.</p>","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596533/pdf/nihms-723300.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34248175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shuo Tian, Qihai Liu, Leonid Gnatovskiy, P. Ma, Zhong Wang
{"title":"Heart Regeneration with Embryonic Cardiac Progenitor Cells and Cardiac Tissue Engineering.","authors":"Shuo Tian, Qihai Liu, Leonid Gnatovskiy, P. Ma, Zhong Wang","doi":"10.19104/JSTB.2015.104","DOIUrl":"https://doi.org/10.19104/JSTB.2015.104","url":null,"abstract":"Myocardial infarction (MI) is the leading cause of death worldwide. Recent advances in stem cell research hold great potential for heart tissue regeneration through stem cell-based therapy. While multiple cell types have been transplanted into MI heart in preclinical studies or clinical trials, reduction of scar tissue and restoration of cardiac function have been modest. Several challenges hamper the development and application of stem cell-based therapy for heart regeneration. Application of cardiac progenitor cells (CPCs) and cardiac tissue engineering for cell therapy has shown great promise to repair damaged heart tissue. This review presents an overview of the current applications of embryonic CPCs and the development of cardiac tissue engineering in regeneration of functional cardiac tissue and reduction of side effects for heart regeneration. We aim to highlight the benefits of the cell therapy by application of CPCs and cardiac tissue engineering during heart regeneration.","PeriodicalId":91131,"journal":{"name":"Journal of stem cell and transplantation biology","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76325614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}